RecruitingNot ApplicableNCT03549559
Imaging Histone Deacetylase in the Heart
Imaging of Histone Deacetylase in the Heart
Sponsor
Massachusetts General Hospital
Enrollment
96 participants
Start Date
Sep 7, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria14
- Group 1: Healthy Volunteers (n = 30)
- Healthy adults with no known history of medical disease
- Age 18-85 years
- No history cardiovascular disease
- Ability to provide informed consent
- Group 2: Patients with Diabetes (n = 16)
- Age 18-85 years
- Diagnosis of diabetes
- Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction
- Ability to provide informed consent
- Group 3: Patients with Aortic Stenosis (n = 50)
- Age 18-85 years
- Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis
- Ability to provide informed consent
Exclusion Criteria1
- Known contraindication to MRI
Interventions
DRUG11C-Martinostat
Imaging probe for evaluating the activity of histone deacetylase in the heart
DEVICEPET-MRI
Siemens PET-MR Scanner (Biograph MMR)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03549559
Related Trials
Diabetes and Heart Disease Risk in Blacks
NCT000018531 location
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
NCT067623141 location
Archival of Human Biological Samples in CU-Med Biobank
NCT047064811 location
Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye
NCT028465712 locations
Exercise Intolerance in Heart Failure
NCT037755771 location